News & Updates
Findings are from the prospective, multicenter VANDAAM trial Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new data from the multicenter, prospective VANDAAM trial show that the Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer among African American men with early-stage disease.…
Read More
Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea OnTarget results in breast cancer patients have been submitted to a relevant oncology conference Excerpt from the Press Release: SAN FRANCISCO, CA / ACCESSWIRE / October 1, 2024 / Jaguar Health, Inc.…
Read More
Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720) Excerpt from the Press Release: CAMBRIDGE, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare…
Read More
Sutter Hill Ventures-led round will accelerate drug pipeline development and advance commercialization efforts, bringing science a step closer to targeting aging Excerpt from the Press Release: REDWOOD CITY, Calif.–(BUSINESS WIRE)–Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics for age-related diseases, today announced that it has…
Read More
First-of-its-kind DNA assay unlocks high-throughput CNV insights critical to cell and gene therapy (CGT) safety and characterizing tumor heterogeneity Excerpt from the Press Release: SAN FRANCISCO, Calif., Sep. 26, 2024 – Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the launch of its Tapestri® Genome Integrity CNV Solution. The new…
Read More
Christopher Kata and the TrialStat team are exhibiting at this years Clinical Outsourcing Group Bay Area meeting on October 8th – 9th in booth #13. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or just drop by booth #13 at your convenience! We’re looking forward to…
Read More
Late Breaking Surgical Safety Data to be Presented This Week at MDS International Congress of Parkinson’s Disease and Movement Disorders Excerpt from the Press Release: SAN DIEGO and PHILADELPHIA , Sept. 26, 2024 /PRNewswire/ — Aspen Neuroscience announced today that it has successfully completed dosing of the first cohort of patients in the ASPIRO study. Surgical safety data…
Read More
New data demonstrate improved hair satisfaction in more than 95% of patients taking deuruxolitinib and clinically meaningful improvements in depression and anxiety from baseline to Week 24 Studies also confirm dose optimization, with results demonstrating greater response with 8 mg tablets twice-daily as compared to higher once-daily dosing Excerpt from the Press Release: MUMBAI, India…
Read More
Trial Initiation Marks Septerna’s Transition to a Clinical-Stage Company Developing a Portfolio of Oral Small Molecule GPCR-Targeted Medicines Phase 1 Clinical Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-786 in Healthy Volunteers Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Septerna, a clinical-stage biotechnology company pioneering a new era of…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced positive 28-week data from the open-label extension (OLE)…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?